• Exchange: NASDAQ GM
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma


1.1000 USD 0.0100 0.90%

As of 20:10:00 ET on 01/23/2015.

Snapshot for ArQule Inc (ARQL)

Open: 1.1000 Day's Range: 1.0800 - 1.1100 Volume: 109,423
Previous Close: 1.1100 52wk Range: 1.0400 - 2.5500 1-Yr Rtn: -56.69%

Stock Chart for ARQL

No chart data available.
  • ARQL:US 1.1000
  • 1D
  • 1M
  • 1Y
Interactive ARQL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for ARQL

Current P/E Ratio (ttm) 0.4402
Estimated P/E(12/2014) -
Relative P/E vs. SPX 0.0242
Earnings Per Share (USD) (ttm) 2.4991
Est. EPS (USD) (12/2014) -0.4700
Est. PEG Ratio -
Market Cap (M USD) 69.05
Shares Outstanding (M) 62.77
30 Day Average Volume 404,813
Price/Book (mrq) 1.5908
Price/Sale (ttm) 6.5499
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 03/05/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for ARQL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for ARQL

ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.

Paolo PucciChief Executive OfficerPeter S LawrencePresident/COO/Secy/Gen Cnsl
Brian SchwartzSenior VP/Chief Medical OfcrWilliam B BoniVP:Investor Relations
More Company Profile & Key Executives for ARQL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Sponsored Links
sec ||= nil